Lantern Pharma Inc (LTRN) Hedge Fund & Institutional Holdings (Q2 2026)

LTRN ranks #6803 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

LTRN is a disclosed holding of Jim Simons (Renaissance Technologies), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

39 institutions disclose a position in LTRN, but none treat it as a major bet — even Empery Asset Management, LP, its most concentrated holder, allocates just 4.1% of its own portfolio to it.

BIOS Capital Management, LP has trimmed its LTRN position for two straight quarters, cutting it by $2.0M while still holding $1.0M.

LTRN is down 0% today, but institutions show net buying of $3.6M this quarter — a divergence between today's price move and the underlying institutional flow.

LTRN reported a net loss of $17.1M in its latest fiscal year.

• Not yet profitable — net loss of $17.1M in the latest fiscal year
• Net income improved year over year, from -$20.8M to -$17.1M
• Operating cash flow was negative, using $15.7M in cash
• Current ratio of 2.40x — enough short-term assets to cover short-term liabilities
• Liabilities run 4001.41x equity — a highly leveraged balance sheet worth noting